Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in High Risk and Premalignant Breast Conditions
NCT02928978Phase 2Completed
- Sponsor
- Julie Nangia
- Start
- May 2018
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ductal carcinoma in situ (DCIS), Atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH) and 1 more comparing Ruxolitinib with Placebo (2 arms). Primary endpoint: Change in Percent of Apoptotic Cells at 15 days. Started May 2018; status: completed.
02
Drugs
03
Conditions
ductal carcinoma in situ (DCIS)Atypical lobular hyperplasia (ALH)atypical ductal hyperplasia (ADH)lobular carcinoma in situ (LCIS)
Beyond the preview
Go deeper on NCT02928978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928978.